Binacea Pharma, a start-up biopharmaceutical company, announced the close of US$20M Series A round of financing, led by investors including Korea Investment Partners, to develop proprietary technologies of next generation bispecific biologics for unmet medical needs in oncology, immunological and neurological diseases.
December 28, 2021 |
-- Multicenter Phase 1 study to evaluate BNA035 as potential immunotherapy for solid tumors--
Hayward, CA, December 28, 2021-- Binacea Pharma, Inc. (“Binacea”), a startup developing innovative bispecific antibodies and antibody-fusion proteins, announced today that it has been granted approval by Therapeutic Goods Administration (TGA) of Australia and Bellberry Human Research Ethics Committee (HREC) in Australia to conduct a Phase 1 clinical study of BNA035 in patients with solid tumors.
This multicenter phase 1 trial is a dose escalation study to evaluate the safety, tolerability and pharmacokinetics of BNA035 in cancer patients with advanced solid tumors. This study may also provide an opportunity to identify preliminary efficacy signals. After determination of the recommended Phase 2 dose, Binacea plans to evaluate the efficacy, safety, and tolerability of BNA035 in expansion cohorts with select types of advanced solid tumors with EGFR over expression.
About BNA035/HLX35
BNA035 (world wide except greater China) is a potential first-in-class bispecific antibody targeting 4-1BB and EGFR. It is also known as HLX35 and is developed by Shanghai Henlius Biotech Inc. in greater China territories. BNA035 not only blocks oncogenic EGFR signal transduction pathways, but also provides clustering and subsequent activation of 4-1BB in immune cells preferentially in tumor microenvironment, as EGFR is overexpressed in a number of solid tumors.
About Binacea Pharma
Binacea Pharma, Inc. is a biotech startup in San Francisco Bay Area. It’s founded by several biotech veterans, each with more than 20 years of experience in biopharmaceutical industry. The company has started its innovation efforts in discovering and developing next generation of antibody drugs to treat cancer, autoimmune and other devastating diseases.
Meanwhile, Binacea is developing proprietary core technology platforms and novel bispecific biologics to address unmet medical needs. For more information, please visit www.binaceapharma.com/
CONTACTS: info@binaceapharma.com
Binacea Pharma Inc. announced in-licensing a bispecific antibody for immuno therapy from Shanghai Henlius Biotech, Inc.
Binacea Pharma, Inc. (“Binacea”), a biotech startup in the San Francisco Bay Area developing innovative bispecific antibodies, announced today that it has reach an agreement with Shanghai Henlius Biotech, Inc. (“Henlius”) to in-license the global rights except greater China territories of Henlius’ proprietary bispecific antibody program, HLX35. HLX35 is also known as BNA035 in the licensed territories. The partners have filed IND (or equivalent) in their respective territories to start Ph1 clinical trials for solid tumors.
About BNA035/HLX35
BNA035/HLX35 is a bispecific antibody targeting 4-1BB and EGFR. It is also known as HLX35 in Greater China territories and is developed by Shanghai Henlius Biotech in these territories. BNA035 not only blocks oncogenic EGFR signal transduction pathways, but also provides clustering and subsequent activation of 4-1BB in immune cells preferentially in tumor microenvironment, as EGFR is overexpressed in a number of solid tumors.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.